Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft II - PRIMO-CABG II


The goal of the trial was to evaluate if treatment with pexelizumab will be associated with a reduction in death or myocardial infarction (MI) at 30 days compared with placebo among patients undergoing coronary artery bypass graft (CABG) surgery.